Associated tags: Therapy, Dermatology, Wart, Molluscum contagiosum, Skin, Pharmaceutical industry, FDA, Patient
Locations: FLORIDA, FL, LONDON, WEST, PENNSYLVANIA, WEST CHESTER, PA, US, TD, MASSACHUSETTS
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:
Key Points:
- WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:
ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
Key Points:
- ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
- Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13746100.
- A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com , or by clicking here .
- A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President & Chief Executive Officer, will present at the upcoming 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from April 8-11, 2024.
Key Points:
- WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President & Chief Executive Officer, will present at the upcoming 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from April 8-11, 2024.
- The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
- A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
The Orange Book,
NCE,
Orange Book,
Dermatology,
Skin,
Patent,
Therapy,
FDA,
Approved drug,
Food,
Pharmaceutical industry WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company’s lead product, YCANTH™, has received New Chemical Entity (“NCE”) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (“FDA”), providing a minimum five years of regulatory exclusivity.
Key Points:
- The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension
WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company’s lead product, YCANTH™, has received New Chemical Entity (“NCE”) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (“FDA”), providing a minimum five years of regulatory exclusivity.
- “We could not be more pleased to announce YCANTH™ has been granted NCE Status by the FDA,” said Ted White, Verrica’s President and Chief Executive Officer.
- “Today’s announcement represents the continued execution of our Company’s comprehensive intellectual property strategy to maximize the patent and regulatory protections surrounding YCANTH™ and further underscores the product’s innovation and intrinsic value in the dermatology market.
- While NCE status will provide YCANTH™ with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond.”
Formally described as the Approved Drug Products with Therapeutic Equivalence Evaluations, the Orange Book is an FDA publication that provides a list of drugs approved as safe and effective and also serves as the regulatory resource for information on drug marketing availability, bioequivalence, drug substitution, and patent and exclusivity data.1 The Orange Book also lists patents covering those drugs, approved methods of their use, and regulatory exclusivities to which they may be entitled.
Retrieved on:
Thursday, February 29, 2024
Torii,
Research,
Calendar,
Chemistry,
Marketing,
FDA,
Table,
Sale,
Travel,
GAAP,
Collaboration,
Patient,
Clinical trial,
Net,
Bank statement,
Insurance,
Pharmaceutical industry WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023.
Key Points:
- Verrica recognized product revenue of $1.9 million in the fourth quarter of 2023.
- Verrica reported a net loss of $24.6 million for the fourth quarter of 2023, compared to a $5.9 million net loss for the same period in 2022.
- Selling, general and administrative expenses were $17.0 million in the fourth quarter of 2023, compared to $3.2 million for the same period in 2022.
- Research and development expenses were $5.3 million in the fourth quarter of 2023, compared to $3.0 million for the same period in 2022.
Retrieved on:
Tuesday, February 27, 2024
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.
Key Points:
- WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.
- The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
- A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
Retrieved on:
Thursday, February 22, 2024
ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.
Key Points:
- ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.
- Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13744217.
- A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com , or by clicking here .
- A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
Dormer,
Sale,
Therapy,
Molluscum contagiosum,
Skin,
Cantharidin,
Safety,
Dermatology,
FDA,
Marketing,
Pharmaceutical industry WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania law. The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.
Key Points:
- The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.
- YCANTH was the first FDA-approved treatment for molluscum contagiosum.
- YCANTH is also the only FDA-approved cantharidin-containing drug, meaning that it is the only cantharidin-containing drug that FDA has determined to be safe and effective.
- This lawsuit is part of Verrica’s commitment to patient safety by stopping the false and misleading advertising and sale of unapproved cantharidin-containing drugs within the United States.
Dermatology,
Medicaid,
Medicare,
Insurance,
Risk,
CMS,
Skin,
FDA,
Molluscum contagiosum,
Therapy,
HCPCS,
Health insurance Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH™ will become fully published April 1, 2024.
Key Points:
- Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH™ will become fully published April 1, 2024.
- J-codes help determine how managed care organizations reimburse medical providers for products and services.
- Inaccurately reporting medical services can cause insurance complications and make it harder to get rebates.
- Using a standardized code reduces the risk of billing errors and allows companies to receive pass-through payments through government-sponsored healthcare plans.1
Part Two,
Skin cancer,
Pain,
Carcinoma,
Patient,
Scar,
Dermatology,
Skin,
Therapy,
Infection,
Part WEST CHESTER, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.
Key Points:
- “We are pleased to announce that Part 2 of our Phase 2 clinical trial of VP-315 for the treatment of basal cell carcinoma has been fully enrolled and the last patient has been dosed,” said Ted White, Verrica’s President and Chief Executive Officer.
- “Basal cell carcinoma is the most common form of skin cancer in the U.S. each year and patients are in need of alternative solutions to surgery which can cause pain, infection and scarring.
- Verrica’s VP-315 program is designed to provide for the targeted delivery of an oncolytic peptide engineered to stimulate the patient’s immune system and destroy cancer cells.
- Our study remains on track, and we look forward to sharing the data from our Phase 2 clinical trial later this year.”
